Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 125 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Timolol (amtlicher ATC-Code: S01ED67)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...

The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude non-exclusive rebate agreements for the pharmaceutical product Brinzolamid/Timolol (eye drops).
  • Supply of the product to pharmacies in the regions of Saxony and Thuringia (Germany) as prescribed by physicians.
Afficher le résumé complet

This is an Open-House model (non-exclusive) for concluding pharmaceutical rebate agreements for the active substance Brinzolamid/Timolol (ATC code S01ED67) under §130a Abs. 8 SGB V. The procedure is open to all interested pharmaceutical companies that meet participation requirements. No individual negotiations, no exclusivity, and no guaranteed minimum purchase quantities. The agreement ends no later than 31.12.2026, but may terminate earlier if exclusive agreements are concluded. Participation requests can be submitted from 03.12.2024, with multiple submission deadlines as per the document 'Einreichungsfristen'. Communication and submission are electronic via DTVP. The buyer is AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen.

Risques

No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...

The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4 Abs. 18 AMG.

Eligibility

  • Submission of a declaration on absence of exclusion grounds (Anlage 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen').

Administrative

  • Declaration regarding EU Russia sanctions (Anlage 'Eigenerklärung Russlandsanktionen').

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; this is an Open-House model, not a competitive award.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol

Single lot covering the entire scope: non-exclusive rebate agreements for Brinzolamid/Timolol. No lot-specific details beyond the overall description.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; this is an Open-House model, not a competitive award.

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication
10 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
683594-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30